% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Mangiapia:20252,
author = {Mangiapia, G. and D'Errico, G. and Simeone, L. and Irace,
C. and Radulescu, A. and DiPascale, A. and Colonna, A. and
Montesarchio, D. and Paduano, L.},
title = {{R}uthenium-based complex nanocarriers for cancer therapy},
journal = {Biomaterials},
volume = {33},
issn = {0142-9612},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {PreJuSER-20252},
pages = {3770 - 3782},
year = {2012},
note = {This work was supported by MIUR (PRIN 2008-prot.
20087K9A2J). The authors thank the Forschungszentrum Julich
for provision of beam time. SANS experiments were supported
by the European Commission, NMI3 contract
RII3-CT-2003-505925.},
abstract = {A new organometallic ruthenium complex, named AziRu, along
with three amphiphilic nucleoside-based ruthenium complexes,
ToThyRu, HoThyRu and DoHuRu, incorporating AziRu in their
skeleton, have been synthesized, stabilized in POPC
phospholipid formulations and studied for their
antineoplastic activity. Self-aggregation behavior of these
complexes was investigated, showing that the three
synthesized AziRu derivatives able to form liposomes and,
under specific conditions, elongated micelles. The
formulations prepared in POPC proved to be stable for months
and showed high in vitro antiproliferative activity. The
here described results open new scenarios in the design of
innovative transition metal-based supramolecular systems for
anticancer drugs vectorization.},
keywords = {Animals / Antineoplastic Agents: administration $\&$ dosage
/ Antineoplastic Agents: chemistry / Cell Line, Tumor / Cell
Survival: drug effects / Drug Carriers / Drug Stability /
Humans / Liposomes / Materials Testing / Microscopy,
Fluorescence / Nanoparticles: administration $\&$ dosage /
Nanoparticles: chemistry / Neoplasms: drug therapy /
Organometallic Compounds: administration $\&$ dosage /
Organometallic Compounds: chemistry / Rats / Ruthenium:
administration $\&$ dosage / Ruthenium: chemistry /
Antineoplastic Agents (NLM Chemicals) / Drug Carriers (NLM
Chemicals) / Liposomes (NLM Chemicals) / Organometallic
Compounds (NLM Chemicals) / Ruthenium (NLM Chemicals) / J
(WoSType)},
cin = {ICS-1 / JCNS (München) ; Jülich Centre for Neutron
Science JCNS (München) ; JCNS-FRM-II / JCNS-1},
ddc = {570},
cid = {I:(DE-Juel1)ICS-1-20110106 /
I:(DE-Juel1)JCNS-FRM-II-20110218 /
I:(DE-Juel1)JCNS-1-20110106},
pnm = {BioSoft: Makromolekulare Systeme und biologische
Informationsverarbeitung (FUEK505) / 544 - In-house Research
with PNI (POF2-544)},
pid = {G:(DE-Juel1)FUEK505 / G:(DE-HGF)POF2-544},
experiment = {EXP:(DE-MLZ)KWS2-20140101},
shelfmark = {Engineering, Biomedical / Materials Science, Biomaterials},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:22357152},
UT = {WOS:000302425400015},
doi = {10.1016/j.biomaterials.2012.01.057},
url = {https://juser.fz-juelich.de/record/20252},
}